共 180 条
[1]
Mears ER(2015)A review: the current in vivo models for the discovery and utility of new anti-leishmanial drugs targeting cutaneous leishmaniasis PLoS Negl Trop Dis 9 1-23
[2]
Modabber F(2015)Cutaneous leishmaniasis: recent developments in diagnosis and management Am J Clin Dermatol 16 99-109
[3]
Don R(2016)Lipid-based nanocarriers for cutaneous leishmaniais and buruli ulcer management Curr Pharm Des 22 6577-6586
[4]
Johnson GE(2015)Cutaneous and mucocutaneous leishmaniasis: differential diagnosis, diagnosis, histopathology, and management J Am Acad Dermatol 73 911-926
[5]
de Vries HJC(2016)The cure rate after placebo or no therapy in American cutaneous leishmaniasis: a systematic review and meta-analysis PLoS One 11 1-15
[6]
Reedijk SH(2015)Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations Clin Infect Dis 60 1398-1404
[7]
Schallig HDFH(2012)Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis Eur J Pharm Sci 45 442-450
[8]
Simoes S(2015)Leishmaniasis: treatment updates and clinical practice guidelines review Curr Opin Infect Dis 28 426-437
[9]
Carvalheiro M(2006)Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin J Parasitol 85 354-705
[10]
Gaspar MM(2010)Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics Clin Exp Dermatol 35 699-123